Evidence map›Paper›PMID 31970200›Full record

ArticleMolecular therapy. Methods & clinical development2020

Mei Hua Gao, Dimosthenis Giamouridis, N Chin Lai, Tracy Guo, Bing Xia, Young Chul Kim, Viet Anh Nguyen Huu, Dorota Skowronska-Krawczyk, Louise Lantier, Raag Bhargava and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Methods & clinical development, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Review
  3. Effects ofHuman gene therapy · 2023
    Article
  4. Human gene therapy · 2022
    Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Mei Hua GaoDepartment of Medicine, University of California, San Diego, La Jolla, CA 92037, USA.
Dimosthenis GiamouridisDepartment of Medicine, University of California, San Diego, La Jolla, CA 92037, USA.
N Chin LaiDepartment of Medicine, University of California, San Diego, La Jolla, CA 92037, USA.
Tracy GuoDepartment of Medicine, University of California, San Diego, La Jolla, CA 92037, USA.
Bing XiaDepartment of Medicine, University of California, San Diego, La Jolla, CA 92037, USA.
Young Chul KimDepartment of Medicine, University of California, San Diego, La Jolla, CA 92037, USA.
Viet Anh Nguyen HuuDepartment of Ophthalmology, University of California, San Diego, San Diego, CA 92103, USA.
Dorota Skowronska-KrawczykDepartment of Ophthalmology, University of California, San Diego, San Diego, CA 92103, USA.
Louise LantierVanderbilt University, Department of Molecular Physiology and Biophysics, Nashville, TN 37232-0615, USA.
Raag BhargavaDepartment of Medicine, University of California, San Diego, La Jolla, CA 92037, USA.
H Kirk HammondDepartment of Medicine, University of California, San Diego, La Jolla, CA 92037, USA.
University of California, San Diego · USVA San Diego Healthcare System · USVanderbilt University · US

Funding

Vector Production CoreP01HL066941 · NHLBI · VETERANS MEDICAL RESEARCH FDN/SAN DIEGO · PI HAMMOND, H. KIRK · 2001 to 2017
$34.8M
Vanderbilt Mouse Metabolic Physiology CenterU24DK059637 · NIDDK · VANDERBILT UNIVERSITY · PI WASSERMAN, DAVID H · 2001 to 2015
$14.9M
Vision BiostatisticsP30EY022589 · NEI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LINDA M ZANGWILL · 2012 to 2026
$10.3M
Transfer: Molecular Mechanisms of GlaucomaR01EY027011 · NEI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SKOWRONSKA-KRAWCZYK, DOROTA · 2017 to 2022
$2.3M
Urocortin-2 Gene Transfer for CHF: a Paracrine Approach Using Intravenous AAV8R42HL122038 · NHLBI · RENOVA THERAPEUTICS, INC. · PI HAMMOND, H. KIRK · 2014 to 2017
$1.8M
ShEEP Request for Comprehensive Lab Animal Monitoring System (CLAMS) / Oxy CLAMSIS1BX004783 · VA · VA SAN DIEGO HEALTHCARE SYSTEM · PI HAMMOND, H. KIRK · 2019 to 2019
–
Translational Studies of Paracrine CV Gene TransferI01BX001515 · VA · VA SAN DIEGO HEALTHCARE SYSTEM · PI HAMMOND, H. KIRK · 2012 to 2015
–
Urocortin 2 Gene Transfer for Heart Failure with Preserved Ejection FractionI01BX003774 · VA · VA SAN DIEGO HEALTHCARE SYSTEM · PI HAMMOND, H. KIRK · 2017 to 2025
–
BLRD VA I01 BX001515BLRD VA I01 BX003774BLRD VA IS1 BX004783NEI NIH HHS P30 EY022589NEI NIH HHS R01 EY027011NHLBI NIH HHS P01 HL066941NHLBI NIH HHS R42 HL122038NIDDK NIH HHS U24 DK059637
6 · The paper itself

Abstract

Type 1 diabetes affects 20 million patients worldwide. Insulin is the primary and commonly the sole therapy for type 1 diabetes. However, only a minority of patients attain the targeted glucose control and reduced adverse events. We tested

Indexed as

Akita MouseAktAMP-activated protein kinaseDiabetic retinopathyGene therapyInsulin sensitivityIntravenous AAV8Islet insulin releaseType 1 diabetes

Identifiers

PMID31970200
PMCPMC6965520
OpenAlexW2995678784

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.